Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) and used in breast cancer, some neuroendocrine tumors, and renal cell carcinoma (RCC) as an antineoplastic agent. The gene discussed is MTOR; the disease is breast carcinoma.